139306-10-8 | 3-[(1S)-1-(Dimethylaminoethyl)]phenol

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$26.00	$18.00
5g	98%	in stock	$79.00	$55.00
25g	98%	in stock	$333.00	$233.00
100g	98%	in stock	$813.00	$569.00

Description

• Catalog Number: AA60364
• Chemical Name: 3-[(1S)-1-(Dimethylaminoethyl)]phenol
• CAS Number: 139306-10-8
• Molecular Formula: C10H15NO
• Molecular Weight: 165.2322
• MDL Number: MFCD06656491
• SMILES: CN([C@H](c1cccc(c1)O)C)C

Computed Properties

• Complexity: 136
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 12
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 1.8

Literature

• Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20120501

• Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.

  Journal of Alzheimer's disease : JAD 20120101

• Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.

  Drug testing and analysis 20100501

• Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

  Electrophoresis 20090201

• Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

  Journal of clinical pharmacology 20080201

• Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

  Clinical pharmacology and therapeutics 20080101

• Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.

  Clinical drug investigation 20080101

• A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.

  Biomedical chromatography : BMC 20040401

• Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

  Biochemistry 20020319